These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
793 related items for PubMed ID: 17064993
1. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN. Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993 [Abstract] [Full Text] [Related]
2. Clinical effect of prophylactic pegfilgrastim in patients with newly diagnosed acute lymphoblastic leukemia who receive intensive chemotherapy. Lee Y, Jang Y, Lee JM, Cho HJ, Moon JH, Sohn SK, Ham JY, Chang SH, Baek DW. Support Care Cancer; 2024 Oct 08; 32(11):715. PubMed ID: 39377915 [Abstract] [Full Text] [Related]
3. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Weiser MA, O'Brien S, Thomas DA, Pierce SA, Lam TP, Kantarjian HM. Cancer; 2002 Jan 15; 94(2):285-91. PubMed ID: 11900213 [Abstract] [Full Text] [Related]
4. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W, International Study Group. Leuk Lymphoma; 2003 Sep 15; 44(9):1503-8. PubMed ID: 14565651 [Abstract] [Full Text] [Related]
5. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC. Leuk Lymphoma; 2003 Oct 15; 44(10):1691-6. PubMed ID: 14692520 [Abstract] [Full Text] [Related]
6. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, Frankel S, Flinn I, Lovelace W, Hackett J, Liang BC. J Clin Oncol; 2003 Feb 01; 21(3):514-9. PubMed ID: 12560443 [Abstract] [Full Text] [Related]
7. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Crawford J. Pharmacotherapy; 2003 Aug 01; 23(8 Pt 2):15S-19S. PubMed ID: 12921218 [Abstract] [Full Text] [Related]
8. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J. Curr Med Res Opin; 2011 Jan 01; 27(1):79-86. PubMed ID: 21091127 [Abstract] [Full Text] [Related]
9. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, Choi IS, Park JH, Choi YJ, Kim HJ, Jung KH, Kim SY, Oh DY, Im SA. Support Care Cancer; 2016 Apr 01; 24(4):1709-17. PubMed ID: 26423618 [Abstract] [Full Text] [Related]
10. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Kubo K, Miyazaki Y, Murayama T, Shimazaki R, Usui N, Urabe A, Hotta T, Tamura K. Br J Haematol; 2016 Aug 01; 174(4):563-70. PubMed ID: 27072050 [Abstract] [Full Text] [Related]
11. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC. Ann Oncol; 2002 Jun 01; 13(6):903-9. PubMed ID: 12123336 [Abstract] [Full Text] [Related]
12. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF. Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N. Clin Ther; 2009 Jun 01; 31 Pt 2():2388-95. PubMed ID: 20110048 [Abstract] [Full Text] [Related]
13. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C. Appl Health Econ Health Policy; 2013 Apr 01; 11(2):129-38. PubMed ID: 23435861 [Abstract] [Full Text] [Related]
14. Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis). Yokoyama M, Kusano Y, Inoue N, Nishimura N, Mishima Y, Nukada T, Hatake K, Terui Y. BMC Cancer; 2021 Apr 06; 21(1):358. PubMed ID: 33823836 [Abstract] [Full Text] [Related]
15. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Lyman G, Lalla A, Barron R, Dubois RW. Curr Med Res Opin; 2009 Feb 06; 25(2):401-11. PubMed ID: 19192985 [Abstract] [Full Text] [Related]
16. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC. J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454 [Abstract] [Full Text] [Related]
17. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia. Ho P, Sherman P, Grigg A. Eur J Haematol; 2012 May 01; 88(5):416-21. PubMed ID: 22296221 [Abstract] [Full Text] [Related]
18. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. Kahan Z, Grecea D, Smakal M, Tjulandin S, Bondarenko I, Perjesi L, Illes A, Horvat-Karajz K, Aradi I. BMC Cancer; 2019 Feb 06; 19(1):122. PubMed ID: 30727980 [Abstract] [Full Text] [Related]
19. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim. Kang KW, Lee BH, Jeon MJ, Yu ES, Kim DS, Lee SR, Sung HJ, Choi CW, Park Y, Kim BS. Cancer Med; 2020 Sep 06; 9(17):6102-6110. PubMed ID: 32633471 [Abstract] [Full Text] [Related]
20. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. J Manag Care Pharm; 2007 May 06; 13(4):337-48. PubMed ID: 17506600 [Abstract] [Full Text] [Related] Page: [Next] [New Search]